QuickView for Trifluoperazine (compound)

Summary
General Info

PubChem

PubChem Compound 2913535

Name:	Trifluoperazine
PubChem Compound ID:	2913535
Description:	A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic.
Molecular formula:	C₂₁H₂₅ClF₃N₃S
Molecular weight:	443.957 g/mol
Synonyms:	SMR000059133; Trifluoperazine dihydrochloride; MLS000069471

DrugBank

Identification

Name:	Trifluoperazine
Name (isomeric):	DB00831
Drug Type:	small molecule
Description:	A phenothiazine with actions similar to CHLORPROMAZINE. It is used as an antipsychotic and an antiemetic.
Synonyms:	Trifluoroperazine Dihydrochloride; Trifluperazine; Trifluoperazine Dihydrochloride; Trifluoperazina; Trifluoroperazine Hydrochloride; Trifluoperazine Hydrochloride; Trifluoperazine HCl; Trifluroperizine; Tryptazine Dihydrochloride; Trifluoroperazine. show more » Trifluoroperazine Dihydrochloride; Trifluperazine; Trifluoperazine Dihydrochloride; Trifluoperazina; Trifluoroperazine Hydrochloride; Trifluoperazine Hydrochloride; Trifluoperazine HCl; Trifluroperizine; Tryptazine Dihydrochloride; Trifluoroperazine; Triphthazine Dihydrochloride; Trifluoromethylperazine; Trifluoperazin show less «
Brand:	Triphthazine, Modalina, Stellazine, Stelazine, Tryptazine, Triphtazin, Fluoperazine, Eskazinyl, Jatroneural, Eskazine, Trazine, Triphthasine, Novo-Trifluzine, Terfluzine, Triperazine, Triftazin, Triftazine, Triphtazine, Synklor, Triflurin
Brand name mixture:	Stelabid No 2(Isopropamide Iodide + Trifluoperazine Hydrochloride), Stelabid No 1(Isopropamide Iodide + Trifluoperazine Hydrochloride), Stelabid Forte(Isopropamide Iodide + Trifluoperazine Hydrochloride), Parmodalin(Tranylcypromine + Trifluoperazine)
Category:	Phenothiazines, Antiemetics, Dopamine Antagonists, Antipsychotic Agents, Antipsychotics
CAS number:	117-89-5

Pharmacology

Indication:	For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Pharmacology:	Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of Action:	Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Biotransformation:	Hepatic.
Half Life:	10-20 hours
Toxicity:	Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Amphetamine	Decreased anorexic effect, may increase psychotic symptoms
Metrizamide	Increased risk of convulsions
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias

Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Amphetamine	Decreased anorexic effect, may increase psychotic symptoms
Metrizamide	Increased risk of convulsions
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias
Tetrabenazine	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
Phentermine	Decreased anorexic effect, may increase psychotic symptoms
Triprolidine	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Phenylpropanolamine	Decreased anorexic effect, may increase psychotic symptoms
Bromocriptine	The phenothiazine decreases the effect of bromocriptine
Donepezil	Possible antagonism of action
Dextroamphetamine	Decreased anorexic effect, may increase psychotic symptoms
Methamphetamine	Decreased anorexic effect, may increase psychotic symptoms
Mazindol	Decreased anorexic effect, may increase psychotic symptoms
Benzphetamine	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Phendimetrazine	Decreased anorexic effect, may increase psychotic symptoms
Galantamine	Possible antagonism of action
Fenfluramine	Decreased anorexic effect, may increase psychotic symptoms
Gatifloxacin	Increased risk of cardiotoxicity and arrhythmias
Trospium	Trospium and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Phenmetrazine	Decreased anorexic effect, may increase psychotic symptoms
Thiabendazole	The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed.
Rivastigmine	Possible antagonism of action
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Guanethidine	Trifluoperazine may decrease the effect of guanethidine.
Diethylpropion	Decreased anorexic effect, may increase psychotic symptoms
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
Trimethobenzamide	Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Dexfenfluramine	Decreased anorexic effect, may increase psychotic symptoms

show less «

Targets

D(2) dopamine receptor

D1 dopamine receptor-interacting protein calcyon

Alpha-1A adrenergic receptor

Calmodulin

Troponin C, slow skeletal and cardiac muscles

Protein S100-A4

Enzymes

Xanthine dehydrogenase/oxidase

UDP-glucuronosyltransferase 1-4

Cytochrome P450 1A2

Transporters

Multidrug resistance protein 1